RESEARCH AND EDUCATION DISCLAIMER
This article summarizes published scientific research for educational purposes only. Level Up Peptides products are intended exclusively for laboratory research by qualified researchers and are not for human or veterinary use. Discussion of published animal or human studies does not recommend those uses or establish the safety or effectiveness of any product sold on this website. This article does not provide medical advice, dosing guidance, or administration instructions.
SUMMARY
CJC-1295 and ipamorelin are research peptides associated with different pathways involved in growth hormone release. Published studies have examined the individual compounds, while older endocrine research provides a rationale for investigating related pathways together. These findings do not establish clinical benefits for the exact CJC-1295–ipamorelin blend. Molecular identity also matters: the long-acting CJC-1295 studied in human trials included an albumin-binding modification, so its results cannot be transferred to materials labeled “No DAC.” [1–4]
WHAT ARE CJC-1295 AND IPAMORELIN?
CJC-1295 is an analogue of growth hormone-releasing hormone, commonly abbreviated GHRH. It was developed to stimulate growth hormone secretion through the GHRH pathway. [1]
Ipamorelin is a synthetic five-amino-acid peptide that acts through the growth hormone secretagogue, or ghrelin, receptor pathway. Its foundational research demonstrated growth hormone release in cultured pituitary cells and animal experiments. Neither compound is growth hormone itself. [2]
WHY DOES THE DAC DISTINCTION MATTER?
The CJC-1295 evaluated in the principal human trial was designed to bind covalently to albumin, a circulating blood protein. This modification, commonly called Drug Affinity Complex or DAC, prolonged its presence in the body. [1]
A material labeled “CJC-1295 No DAC” lacks that defining albumin-binding modification and must not be treated as the same study material. In particular, the published multi-day half-life and prolonged hormone responses cannot be assumed to apply to a No DAC blend.
For research interpretation, a product name alone is insufficient. The documented molecular structure must match the compound described in the cited study.
WHAT DID THE CJC-1295 HUMAN TRIAL MEASURE?
A 2006 publication reported two randomized, placebo-controlled trials lasting 28 and 49 days. The albumin-binding CJC-1295 increased growth hormone and insulin-like growth factor 1, or IGF-1, in healthy adults. Researchers estimated a half-life of approximately six to eight days. [1]
These were hormone-response and pharmacokinetic studies. Their findings did not establish muscle growth, improved sleep, injury recovery, or longer life.
WHAT HAS BEEN SHOWN FOR IPAMORELIN?
A 1999 study examined ipamorelin in healthy male volunteers. Researchers measured its disappearance from the bloodstream and the associated growth hormone response. Under the study’s intravenous administration conditions, the estimated terminal half-life was about two hours, and growth hormone showed a temporary rise followed by a decline. [3]
That result describes a particular route and experimental setting. It does not establish how a blended research material behaves under other conditions.
Ipamorelin is also frequently described as selective for growth hormone release. The foundational 1998 study evaluated this selectivity in animals, including pigs. Ipamorelin produced ACTH and cortisol responses that were not significantly different from those produced by GHRH, while comparison compounds produced larger responses. [2]
This is more precise than saying ipamorelin never affects other hormones. Animal selectivity findings do not establish freedom from adverse effects in humans.
HAS SYNERGY BEEN PROVEN FOR THE EXACT BLEND?
A 1990 study in 18 men found that combining GHRH with an older growth hormone-releasing peptide produced a greater growth hormone response than expected from simply adding the separate responses. This supports the biological rationale for studying the two pathways together. [4]
However, that experiment did not use CJC-1295 and ipamorelin. It cannot establish the magnitude, duration, or safety of a response to their combination.
The studies cited here therefore support a research hypothesis about complementary signaling. They do not demonstrate that the exact blend produces superior clinical outcomes, and they do not establish a particular degree of synergy for a No DAC formulation.
WHY ARE HORMONE CHANGES DIFFERENT FROM CLINICAL BENEFITS?
A hormone measurement can show that a compound has biological activity. Demonstrating a useful outcome requires measuring that outcome directly, such as strength, physical function, or recovery.
Ipamorelin has also undergone research outside growth hormone testing. A 2014 randomized, placebo-controlled trial enrolled 117 people undergoing bowel surgery and evaluated postoperative gastrointestinal recovery. The difference in time to tolerate a solid meal did not reach statistical significance. [5]
That trial concerned ipamorelin alone and a specific postoperative condition. It neither validates the CJC-1295–ipamorelin combination nor establishes benefits for body composition.
WHAT REMAINS UNCERTAIN?
Evidence from an individual compound cannot substitute for testing a mixture. Combining peptides may change exposure and biological responses, while formulation stability and compatibility require separate investigation.
The cited studies do not establish the long-term safety or clinical effectiveness of a CJC-1295–ipamorelin blend. Claims about muscle gain, fat reduction, sleep improvement, recovery, or anti-aging should not be presented as demonstrated outcomes of these studies.
Published research also does not confirm the identity, purity, stability, or biological performance of a separately supplied laboratory product. Those characteristics require documentation and testing specific to the material being studied.
REFERENCES
Some study titles are shortened for readability. Each link identifies the original source.
[1] Teichman SL, Neale A, Lawrence B, et al. Prolonged stimulation of GH and IGF-I secretion by CJC-1295 in healthy adults. Journal of Clinical Endocrinology & Metabolism. 2006;91(3):799–805.
https://doi.org/10.1210/jc.2005-1536
[2] Raun K, Hansen BS, Johansen NL, et al. Ipamorelin, the first selective growth hormone secretagogue. European Journal of Endocrinology. 1998;139(5):552–561.
https://doi.org/10.1530/eje.0.1390552
[3] Gobburu JVS, Agersø H, Jusko WJ, Ynddal L. Pharmacokinetic-pharmacodynamic modeling of ipamorelin, a growth hormone releasing peptide, in human volunteers. Pharmaceutical Research. 1999;16(9):1412–1416.
https://doi.org/10.1023/A:1018955126402
[4] Bowers CY, Reynolds GA, Durham D, et al. Growth hormone-releasing peptide stimulates GH release in normal men and acts synergistically with GH-releasing hormone. Journal of Clinical Endocrinology & Metabolism. 1990;70(4):975–982.
https://doi.org/10.1210/jcem-70-4-975
[5] Beck DE, Sweeney WB, McCarter MD; Ipamorelin 201 Study Group. Randomized study of ipamorelin for postoperative ileus in bowel resection patients. International Journal of Colorectal Disease. 2014;29(12):1527–1534.